Arcellx

Arcellx FCF Growth

Delisted

The Year-over-Year Free Cash Flow Growth of Arcellx (ACLX) as of Nov 21, 2026 is -119.38 %. In the previous year, Year-over-Year Free Cash Flow Growth was -152.06 % — a change of -21.49% (higher).

FCF Growth

-119.38 %

YoY

-21.49%

Last updated:

Year-over-Year Free Cash Flow Growth of Arcellx is 2025 -119.38 % . Year-over-Year Free Cash Flow Growth of Arcellx was 2024 -152.06 % . It decreases by -21.49% higher compared to the previous year.

The Arcellx FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-207.96 USD
Jan 1, 2020
-30.73 USD
Jan 1, 2021
-103.12 USD
Jan 1, 2022
-69.24 USD
Jan 1, 2023
283.25 USD
Jan 1, 2024
-152.06 USD
Jan 1, 2025
-119.38 USD
The Arcellx FCF Growth history
YEARFCF GrowthYoY
-119.38 %-21.49%
-152.06 %-153.68%
283.25 %-509.08%
-69.24 %-32.85%
-103.12 %+235.57%
-30.73 %-85.22%
-207.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Year-over-Year Free Cash Flow Growth of Arcellx is -119.38 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Arcellx since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Arcellx

All Key Metrics — Arcellx